Kiniksa Pharmaceuticals International, plc $KNSA Stake Raised by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. increased its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 12.4% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 225,374 shares of the company’s stock after purchasing an additional 24,800 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Kiniksa Pharmaceuticals International were worth $8,751,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC raised its stake in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares in the last quarter. Osaic Holdings Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International during the second quarter valued at $31,000. USA Financial Formulas acquired a new position in shares of Kiniksa Pharmaceuticals International during the third quarter valued at $32,000. Quantbot Technologies LP bought a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter valued at about $43,000. Finally, Farther Finance Advisors LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 582.4% during the third quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company’s stock valued at $53,000 after purchasing an additional 1,159 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA opened at $47.77 on Friday. The firm’s 50 day moving average is $42.72 and its 200-day moving average is $39.37. Kiniksa Pharmaceuticals International, plc has a 12-month low of $18.25 and a 12-month high of $47.86. The stock has a market capitalization of $3.62 billion, a P/E ratio of 106.16 and a beta of 0.06.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, Director Barry D. Quart sold 20,129 shares of the company’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $41.51, for a total value of $835,554.79. Following the transaction, the director owned 12,546 shares of the company’s stock, valued at approximately $520,784.46. This represents a 61.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Mark Ragosa sold 42,841 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average price of $41.49, for a total value of $1,777,473.09. Following the sale, the chief financial officer owned 31,086 shares of the company’s stock, valued at $1,289,758.14. This trade represents a 57.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 123,823 shares of company stock worth $5,244,967. 53.48% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on KNSA shares. Wedbush increased their target price on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Zacks Research cut Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Finally, The Goldman Sachs Group increased their price target on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.71.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.